Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 4/20 | 0.38 |
| ▸ | MAPK13 | O15264 | 3/20 | 0.38 |
| ▸ | MAPK12 | P53778 | 3/20 | 0.38 |
| ▸ | MAPK11 | Q15759 | 3/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.32 |
| ▸ | KCNH3 | Q9ULD8 | 1/20 | 0.31 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3228371 | 0.88 | MAPK14 (0.35) | MAPK14MAPK13MAPK12MAPK11KCNH2 | |
| SCHEMBL1066098 | 0.87 | MAPK14 (0.41) | MAPK14MAPK13MAPK12MAPK11KCNH2 | |
| Dilmapimod SCHEMBL29372394 | 0.85 | MAPK14 (0.47) | MAPK14MAPK13MAPK12MAPK11KCNH2 | |
| Dilmapimod SCHEMBL29379709 | 0.85 | MAPK14 (0.47) | MAPK14MAPK13MAPK12MAPK11KCNH2 | |
| Dilmapimod SCHEMBL1065268 | 0.85 | MAPK14 (0.47) | MAPK14MAPK13MAPK12MAPK11KCNH2 | |
| Dilmapimod SCHEMBL29528002 | 0.85 | MAPK14 (0.47) | MAPK14MAPK13MAPK12MAPK11KCNH2 | |
| SCHEMBL3222339 | 0.84 | MAPK14 (0.38) | MAPK14MAPK13MAPK12MAPK11KCNH2 | |
| SCHEMBL3221484 | 0.84 | MAPK14 (0.35) | MAPK14MAPK13MAPK12MAPK11KCNH2 | |
| SCHEMBL3213025 | 0.84 | MAPK14 (0.37) | MAPK14MAPK13MAPK12MAPK11KCNH2 | |
| SCHEMBL2718489 | 0.83 | MAPK14 (0.40) | MAPK14MAPK13MAPK12MAPK11KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100069409-A1 | \"NOVEL COMPOUNDS\ | GLAXO GROUP LIMITED (GB) | 2010-03-18 | — | — | US | disclosed |
| US-7479558-B2 | Process for preparing pyrido[2,3-d]pyrimidin-7-one and 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one derivatives | GLAXO GROUP LIMITED (GB) | 2009-01-20 | — | — | US | disclosed |
| US-20080096905-A1 | Process For Preparing Pyrido[2,3-D]Pyrimidin-7-One And 3,4-Dihydropyrimido{4,5-D}Pyrimidin-2(1H)-One Derivatives | GLAXO GROUP LIMITED (GB) | 2008-04-24 | — | — | US | disclosed |
| US-20060258687-A1 | Process for preparing pyrido[2,3-d]pyrimidin-7-one and 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one derivatives | GLAXO GROUP LIMITED (GB) | 2006-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258687-A1 | Process for preparing pyrido[2,3-d]pyrimidin-7-one and 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one derivatives | CBR3, CBR1, CYP2S1 | MAPK14 4279/4885MAPK13 3921/4885MAPK12 4330/4885 |
| US-20080096905-A1 | Process For Preparing Pyrido[2,3-D]Pyrimidin-7-One And 3,4-Dihydropyrimido{4,5-D}Pyrimidin-2(1H)-One Derivatives | CYP2S1, CYP2F1, CBR3 | MAPK14 3858/4885MAPK13 3664/4885MAPK12 4244/4885 |
| US-20100069409-A1 | \"NOVEL COMPOUNDS\ | MAPKAPK2, CDC42BPB, MAP4K2 | MAPK14 60/4885MAPK13 58/4885MAPK12 103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.